05/05/2025 – AB Science announced that new analyses from its phase 3 trial in ALS and preclinical animal model data have been accepted for presentation at the ENCALS annual meeting (June 3-6, 2025, Turin, Italy) Download PDF Post navigationPreviousPrevious post:AB Science will publish its 2024 annual financial report on May 9, 2025NextNext post:Annual financial results as of 31 December, 2024Related PostsAB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025AB Science announces the successful completion of a EUR 1.925 million private placementJuly 8, 2025Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025
Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025
New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025
